Bausch Health Companies Inc. Common Stock (NY:BHC)

5.845 -0.085 (-1.43%)

Delayed Quote Updated: 2:30 PM EDT, Oct 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Bausch Health Companies Inc. Common Stock

< Previous 1 2

...

8 9 10 11 12 13 14 15 Next >

Jim Cramer's Top Stocks For 2022: Eli Lilly, Honeywell And More ↗

January 05, 2022

Jim Cramer announced his top stock picks for 2022 Wednesday on CNBC's "Fast Money Halftime Report." The fo...

Via Benzinga

Stock Market Crash Coming? 7 Wall Street Pros Make Their Predictions ↗

December 29, 2021

December is when analysts and banks issue their extensive stock market outlook and winning stocks for the new year.

Via InvestorPlace

BHC Stock: 9 Things to Know as Jim Cramer Buys Bausch Health ↗

December 20, 2021

The Mad Money host announced a new position in Bausch Health amid the spread of the omicron variant. Here's what you should know.

Via InvestorPlace

4 Stocks Insiders Are Buying ↗

December 03, 2021

When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, t...

Via Benzinga

Unusual Options Activity Insight: Bausch Health Companies ↗

August 06, 2021

Bausch Health Companies (NYSE:BHC) shares experienced unusual...

Via Benzinga

Unusual Options Activity Insight: Bausch Health Companies ↗

August 04, 2021

Bausch Health Companies (NYSE:BHC) shares experienced unusua...

Via Benzinga

Why Did Bausch Health Shares Plunge Today? ↗

November 02, 2021

Bausch Health Companies Inc (NYSE: BHC) reported Q3 revenues of $2.111 billion, down 1% Y/Y, missing the consensus of $2.66 billion. Excluding the impact of foreign...

Via Benzinga

Bausch Health Companies inc (BHC) Q3 2021 Earnings Call Transcript ↗

November 02, 2021

BHC earnings call for the period ending October 2, 2021.

Via The Motley Fool

Topics Earnings

The Week Ahead In Biotech (Oct. 24-30): Eyenovia, ANI Pharma, Clearside Medical FDA Decisions, Merck, Bristol-Myers Squibb Earnings, IPOs And More ↗

October 24, 2021

Biotech stocks posted gains for the second week running, supported by multiple catalysts that included a good start to the big pharma reporting season and broader market strength...

Via Benzinga

The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline ↗

October 31, 2021

Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc...

Via Benzinga

The Daily Biotech Pulse: FDA Authorizes Moderna, J&J Booster Shots; Regulatory Approvals For Bristol-Myers Squibb, Sanofi-Regeneron; Ventyx IPO ↗

October 21, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus CDC Committee Recommends Approval Of Merck, Pfizer's Pneumococcal Vaccine...

Via Benzinga

Friday Market Coverage ↗

October 08, 2021

New hiring again failed to rise in Sept., the 2nd month in a row which may be good news because it could delay the Fed tapering.

Via Talk Markets

Topics Economy

Attention Biotech Investors: Mark Your Calendar For October PDUFA Dates ↗

October 01, 2021

Following a mixed month for regulatory approvals, biotech investors now turn toward a month of plenty as far as Food and Drug Administration decisions are concerned. Four new...

Via Benzinga

Why Bausch Health Companies Stock Zoomed 8% Higher Today ↗

September 21, 2021

One analyst crunches the numbers to come up with a share price valuation well above current levels.

Via The Motley Fool

NYSE: BHC Shareholder Notice: Investigation over Potential Wrongdoing at Bausch Health Companies Inc. ↗

September 13, 2021

San Diego, CA -- (SBWIRE) -- 09/13/2021 -- An investigation on behalf of investors in Bausch Health Companies Inc. (NYSE: BHC) shares over potential wrongdoing at Bausch Health Companies Inc. was...

Via SBWire

Topics Supply Chain

Bausch Pays $300M For Diabetes Drug Lawsuit: Reuters ↗

September 10, 2021

Reuters reports that Bausch Health Companies Inc (NYSE: BHC) will pay $300 million to settle an antitrust lawsuit related to illegally maintaining a monopoly on...

Via Benzinga

Topics Lawsuit

Bausch Health Companies Inc. (NYSE:BHC) Investor Notice: Investigation over Possible Violations of Securities Laws ↗

August 16, 2021

San Diego, CA -- (SBWIRE) -- 08/16/2021 -- Bausch Health Companies Inc is under investigation over potential securities laws in connection with certain financial statements.

Via SBWire

Topics Supply Chain

Why Bausch Health Companies Is Plunging Today ↗

August 03, 2021

The turnaround isn't happening as fast as investors expected.

Via The Motley Fool

Topics Product Recall

Q2 13F Roundup: How Buffett, Einhorn, Ackman And Others Adjusted Their Portfolios ↗

August 17, 2021

The latest round of 13F filings from institutional investors is out, revealing to the world the stocks that some of the richest and most successful investors have been buying and...

Via Benzinga

75 Biggest Movers From Yesterday ↗

August 04, 2021

Gainers Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) shares climbed 68.1% to close at $58.25 on Tuesday after the company announced that the it has received approval for a...

Via Benzinga

Bausch Health Companies inc (BHC) Q2 2021 Earnings Call Transcript ↗

August 03, 2021

BHC earnings call for the period ending June 30, 2021.

Via The Motley Fool

Topics Earnings

48 Stocks Moving In Tuesday's Mid-Day Session ↗

August 03, 2021

Gainers Wilhelmina International, Inc. (NASDAQ: WHLM) shares jumped 64.4% to $7.15 after a Form 4 filing from the company showed 10% shareholder Retail Ecommerce Ventures...

Via Benzinga

Bausch Health Misses On Q2 Sales, Cuts FY21 Outlook, Plans IPO For Medical Aesthetics Business ↗

August 03, 2021

Bausch Health Companies Inc (NYSE: BHC) has reported Q2 revenues of $2.1 billion, +26% Y/Y, and missing the consensus of $2.12 billion. Revenue increased organically by...

Via Benzinga

Topics Initial Public Offering

Earnings Outlook For Bausch Health Companies ↗

August 02, 2021

Bausch Health Companies (NYSE:BHC) releases its next round of earnings this Tuesday, August 03. Here is Benzinga's essential guide to Bausch Health Companies's Q2 earnings report...

Via Benzinga

The Daily Biotech Pulse: Sanofi Buys Translate Bio In $3.2B Deal, Lilly's Q2 Earnings Disappoint, Bausch To Spin Off Medical Aesthetics Business ↗

August 03, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 2) Absci, CORP (NASDAQ: ABSI) (...

Via Benzinga

Unusual Options Activity Insight: Bausch Health Companies ↗

July 28, 2021

Shares of Bausch Health Companies (NYSE:BHC) saw some unusual options activity on Wednesday. Following the unusual option alert, the stock price moved up to $28.94. Sentiment:...

Via Benzinga

Analyzing Bausch Health Companies's Unusual Options Activity ↗

July 15, 2021

On Thursday, shares of Bausch Health Companies (NYSE:BHC) saw unusual options activity. After the option alert, the stock price moved down to $28.52. Sentiment: BEARISH Option...

Via Benzinga

New Month And Half Year ↗

July 01, 2021

Welcome to H2. In theory, if markets did well in H1 they tend to close the year up.

Via Talk Markets

Reconsidered Boom ↗

June 22, 2021

The US markets tried to repeat the big rise from yesterday, and appears to have succeeded.

Via Talk Markets

Charles River's Jim Foster Beat The Trauma Of Being CEO ↗

June 10, 2021

Think taking over the family business is easy? Charles River CEO Jim Foster might beg to differ. He's shown that being CEO comes with trauma.

Via Investor's Business Daily

< Previous 1 2

...

8 9 10 11 12 13 14 15 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.